Advertisement
Advertisement
PRTA
Prothena Corporation plc Ordinary Shares
8.76
USDSponsored
+0.18
+2.10%
Aug 07, 15:59 UTC -4
Closed
After-Market
9.13
+0.37
+4.27%
PRTA Earnings Reports
Positive Surprise Ratio
PRTA beat 21 of 42 last estimates.
50%
Next Report
Date of Next Report
Nov 04, 2026
Estimate for Q3 26 (Revenue/ EPS)
$11.53M
/-$0.21
Implied change from Q2 26 (Revenue/ EPS)
+1041.79%
/-34.38%
Implied change from Q3 25 (Revenue/ EPS)
+377.52%
/-69.12%
Prothena Corporation plc Ordinary Shares earnings per share and revenue
On Aug 06, 2026, PRTA reported earnings of -0.32 USD per share (EPS) for Q2 26, beating the estimate of -0.39 USD, resulting in a 19.76% surprise. Revenue reached 1.01 million, compared to an expected 28.86 million, with a -96.50% difference. The market reacted with a +2.10% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 11.53 million USD, implying an decrease of -34.38% EPS, and increase of 1041.79% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Monte Rosa Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.43
Surprise
-9.58%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prime Medicine, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.26
Actual
-$0.24
Surprise
+8.57%
Ocugen, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.07
Surprise
-26.35%
X4 Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Cellectis S.A. - ADR
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.22
Surprise
+20.89%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Aligos Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$1.09
Actual
-$0.14
Surprise
+87.21%
FAQ
What were Prothena Corporation plc Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Prothena Corporation plc Ordinary Shares reported EPS of -$0.32, beating estimates by 19.76%, and revenue of $1.01M, -96.5% below expectations.
How did the market react to Prothena Corporation plc Ordinary Shares's Q2 2026 earnings?
The stock price moved up 2.1%, changed from $8.58 before the earnings release to $8.76 the day after.
When is Prothena Corporation plc Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 04, 2026.
What are the forecasts for Prothena Corporation plc Ordinary Shares's next earnings report?
Based on 4
analysts, Prothena Corporation plc Ordinary Shares is expected to report EPS of -$0.21 and revenue of $11.53M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement